Adaptimmune Shares Rise After Asset Sale Agreement

Adaptimmune Therapeutics shares are trading higher after the company agreed to sell its cell therapies to US WorldMeds for up to $85M, despite H.C. Wainwright downgrading the stock to Neutral.